Vaxart’s (VXRT) Stock Will Surge 130% From Current Levels, Says Analyst

Vaccine specialist Vaxart (VXRT) reported 2Q20 earnings last week, but since its vaccine candidates are all in development, the results themselves were of little importance. More pertinent for investors were updates on the pipelines progress. Specifically, Vaxarts COVID-19 oral vaccine candidate.
As the only oral vaccine to be selected for inclusion in the governments Operation Warp Speed (OWS) program, Vaxarts offering has shown promise in pre-clinical trials, with a Phase 1 study expected to …

Click here to view the original article.